ITM Isotope Technologies Munich SE (ITM) and Institut Laue-Langevin (ILL) today announced an extension of their collaboration for medical radioisotope production , originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at the ILL’s High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. ¹⁷⁷Lu), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis.

A patch containing tens of millions of microscopic nanoneedles could soon replace traditional biopsies, scientists have found. The patch offers a painless and less invasive alternative for millions of patients worldwide who undergo biopsies each year to detect and monitor diseases like cancer and Alzheimer’s.

https://doi.org/10.1007/s42995-024-00264-8

Announcing a new publication for Marine Life Science & Technology journal. In this research article Professor Chundi Wang from the Marine College of Shandong University, Weihai, China considers some long-standing taxonomic uncertainties and evolutionary relationships within Scuticociliatia, a diverse group of ciliates.

Rational design of multifunctional nanoplatforms capable of combining therapeutic effects with real-time monitoring of drug distribution and tumor status is emerging as a promising approach in cancer nanomedicine. Here, we introduce pyropheophorbide a–bisaminoquinoline conjugate lipid nanoparticles (PPBC LNPs) as a bimodal system for image-guided phototherapy in bladder cancer treatment. PPBC LNPs not only demonstrate both powerful photodynamic and photothermal effects upon light activation, but also exhibit potent autophagy blockage, effectively inducing bladder cancer cell death. Furthermore, PPBC LNPs possess remarkable photoacoustic (PA) and fluorescence (FL) imaging capabilities, enabling imaging with high-resolution, deep tissue penetration and high sensitivity for tracking drug biodistribution and phototherapy efficacy. Specifically, PA imaging confirms the efficient accumulation of PPBC LNPs within tumor and predicts therapeutic outcomes of photodynamic therapy, while FL imaging confirms their prolonged retention at the tumor site for up to 6 days. PPBC LNPs significantly suppress bladder tumor growth, with several tumors completely ablated following just two doses of the nanoparticles and laser treatment. Additionally, PPBC LNPs were formulated with lipid-based excipients and assembled using microfluidic technology to enhance biocompatibility, stability, and scalability, showing potential for clinical translation. This versatile nanoparticle represents a promising candidate for further development in bladder cancer therapy.